InvestorsHub Logo
Followers 4
Posts 1006
Boards Moderated 0
Alias Born 07/27/2011

Re: None

Thursday, 02/15/2018 12:51:37 PM

Thursday, February 15, 2018 12:51:37 PM

Post# of 20689
Per the CC call this am. they are going to start spending less on BioSimilars, as they have more time to market due to lengthy litigation, and spend more on novel drugs. Less litigation delays than with Biosimilars. Less competition with the novel drugs.

Glad to hear that. I have wondered why they were not considering that. Probably a lot more money to be made on being first on a novel drug.

Boing X 2